Using samples collected from prospective and retrospective patient cohorts and a cell bank containing human leukocyte antigen (HLA) typed lymphocytes from 1,200 healthy donors, we identify key parameters associated with different clinical phenotypes of hypersensitivity and characterise the structure of drug peptide antigens presented to immune cells.
The overarching aim of this research programme is to provide a comprehensive understanding of the chemical, genetic and molecular basis of drug hypersensitivity. The results of this will positively impact on clinical practice through application of diagnostic tests, and the pharmaceutical industry through the development of a stepwise screening approach to assess the intrinsic immunogenicity of new drugs.
CDSS investigators
Back to: Centre for Drug Safety Science
